NYX-783, an NMDA receptor modulator, showed statistically significant and clinically meaningful efficacy with a favorable safety profile.
Participants receiving either 10 mg or 50 mg of NYX-783 once daily demonstrated statistically significant improvements in a PTSD scale called CAPS-5 compared to placebo.
At week 4, 78% of subjects in the intent-to-treat population receiving 50 mg achieved a 30% improvement from baseline in CAPS-5 Total Score versus 44% in the control arm. 50% of this same group achieved a 50% improvement in CAPS-5 Total Score at week 4 compared to 26% in the placebo group.
Management will host a conference call tomorrow, October 20, at 8:30 am ET to discuss the results.